NeoMTA 2


Clinical feedback and continuous improvement through ongoing product development is the foundation for our newest powder/liquid MTA product. Introducing NeoMTA® 2 – Our second-generation highly versatile root & pulp treatment material with improved features.
Features & Benefits
Designed to be easier to mix.
30% higher radiopacity than NeoMTA Plus (6.5 vs 5.0 mm equivalent aluminum as a putty-like mixture).
Brighter white.
See more

SKU: N/A Categories: , ,



  • Direct and indirect pulp capping
  • Partial pulpotomy
  • Cavity liner and base
  • Pulpotomy and apexogenesis
  • Perforation repair
  • Root resorption
  • Sealing
  • Obturation
  • Root apexification
  • Root-end filling

Features & Benefits

    Bioactive Bioceramic
  • Promotes the formation of hydroxyapatite on the surface to seal and support healing through the release calcium and hydroxide ions.
  • Biocompatible, Non-cytotoxic, Non-genotoxic, initially high in pH (alkaline/basic), which has shown to be antimicrobial in-vitro1.
  • Resin-Free
  • Dimensionally stable with no shrinkage to ensure a gap-free seal, minimizing opportunity for bacterial infiltration.
  • Resin-free for maximum bioactivity.
  • Easier to Mix
  • Our improved gel formula allows for an easier mixing process.
  • 30% Higher Radiopacity
  • 6.5 mm AI equivalent radiopacity when mixed to a firm putty.
  • Brighter white Non-Staining
  • Won’t discolor teeth – EVER. NaOCI won’t cause discoloration.
  • 3-year shelf life


SKU N2250- Professional Kit – one 2.5 gm – 25 doses3
SKU AMTA2SB – Smart bundle – three 2.5 gm kits – 75 doses3

1NeoPUTTY is initially high in pH (alkaline/basic) when applied. Literature has shown such products to be antimicrobial in-vitro.
The anti-microbial effect against enterococcus faecalis and the compressive strength of two types of mineral trioxide aggregate mixed with sterile water or 2% chlorhexidine liquid. Holt DM, Watts JD, Beeson TJ, Kirkpatrick TC, Rutledge RE. J Endod. 2007 Jul;33(7):844-7.
3The # of doses varies depending on the treatment. A dose size of 0.1 gm was used here.
A Randomized Clinical Trial of NeoMTA Plus in Primary Molar Pulpotomies.
The purpose of this study was to compare the success of pulpotomies in primary molars using a new type of mineral trioxide aggregate (MTA; NeoMTA Plus) with a conventional MTA (ProRoot MTA) as a pulpotomy medicament in primary molars.
Read more
Bioactive tri/dicalcium silicate cements for treatment of pulpal and periapical tissues.
This review emphasizes research on how these materials have conformed to international standards for dental materials ranging from biocompatibility (ISO 7405) to conformance as root canal sealers (ISO 6876).
Read more
Histology of NeoMTA Plus and Quick-Set2 in Contact with Pulp and Periradicular Tissues in a Canine Model.
The purpose of this study was to compare the healing of pupal and periapical tissues in dogs after exposure to NeoMTA Plus and Quick-Set2 after pulpotomy and root-end surgery procedures.
Read more
Dentinal Tubule Penetration of Tricalcium Silicate Sealers.
Smaller particle size and easier handling properties have allowed the advent of tricalcium silicate sealers. The objective of this study was to measure the tubule penetration with these sealers using continuous wave (CW) and single-cone (SC) obturation techniques.
Read more

Unlike inert resin and ZOE materials, MTA provides state-of-the-art Bioactive technology
to promote bioactivity and support healing.

After placement of MTA in the tooth, body fluids infiltrate the material to cause setting.

During this process, calcium and hydroxide ions are released from the MTA, promoting hydroxyapatite (HA) formation on the MTA surfaces.

When HA coats the surface, it hides the underlying MTA to minimize foreign body reactions and support healing responses of the pulpal or periapical tissue.

Calcium phosphate precipitated crystals scattered on the hydrated tricalcium silicate cement surface1.

High magnification image of the calcium phosphate crystals1.

MTA-Based Bioactivity
Hydroxyapatite forms to ensure Bioactive sealing.

Dr. Brett Gilbert, founder of Access Endo interview NeoPUTTY inventor Dr Carolyn Primus PhD

Additional information

NeoMTA kit or bundle

Professional Kit – 2.5gm, Smart Bundle – three 2.5gm kits